{
    "clinical_study": {
        "@rank": "6595", 
        "arm_group": [
            {
                "arm_group_label": "ARM A", 
                "arm_group_type": "Experimental", 
                "description": "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6."
            }, 
            {
                "arm_group_label": "ARM  B", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone."
            }
        ], 
        "brief_summary": {
            "textblock": "In this study, the investigators assessed whether intraoperative Intraportal infusion of\n      5-FU and oxaliplatin is able to prevent liver metastasis in patients receiving curative\n      colorectal cancer resection."
        }, 
        "brief_title": "Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Neoplasm Metastasis", 
            "Liver Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms", 
                "Liver Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this study, the investigators assessed whether intraoperative Intraportal infusion of\n      5-FU and oxaliplatin is able to prevent liver metastasis and improve  survival in patients\n      with Stage II or Stage III colorectal cancer without apparent liver metastasis based on a\n      thorough preoperative evaluation.\n\n      Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two\n      arms.Arm A: 5-FU 1g and oxaliplatin 100mg + curative resection (study group, n=132). Arm B:\n      curative resection alone (control group, n=132).Follow-up: X-ray, US, CT, blood test,\n      colonoscopy,every 3months.\n\n      The study endpoints were disease-free survival, overall survival, and liver metastasis-free\n      survival as evaluated by intent-to-treat analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Age \u2265 18 and \u2264 75 years and with histologically proven adenocarcinoma of the colon or\n             rectum\n\n          2. WHO performance status of 0 or 1\n\n          3. Stage II (T3-4, N0, M0) or Stage III (T0-4, N1-2, M0) disease (according to the 1997\n             revision of the International Union Against Cancer TNM staging system) as determined\n             by a preoperative evaluation that included colonoscopy and an abdominal computed\n             tomography (CT) scan\n\n          4. Written informed consent for participation in the trial.\n\n        Exclusion criteria\n\n          1. has prior other malignant cancer\n\n          2. has severe major organ dysfunction\n\n          3. has prior cancer therapy before surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972503", 
            "org_study_id": "Octree Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARM A", 
                "description": "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.", 
                "intervention_name": "5-FU and oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ARM A", 
                    "ARM  B"
                ], 
                "description": "Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).", 
                "intervention_name": "colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Colorectal Neoplasms", 
            "Liver", 
            "Neoplasm Metastasis", 
            "Tegafur", 
            "oxaliplatin"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "xujmin@aliyun.com", 
                "last_name": "jianmin Xu, PHD", 
                "phone": "008613501984869"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200000"
                }, 
                "name": "Zhongshan Hospital, Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.", 
        "overall_contact": {
            "email": "xujmin@aliyun.com", 
            "last_name": "jianmin Xu, PHD", 
            "phone": "008613501984869"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PFS will be defined as the period from the first day of CRC resection to the date of disease recurrence or to death.", 
            "measure": "3 years disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "3 years after operation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972503"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xu jianmin", 
            "investigator_title": "Jianmin Xu, PhD Fudan University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "3 years overall survival and metastasis-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "3 years after operation"
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xu jianmin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}